Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.98 USD | +0.59% | +1.34% | -0.39% |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.95B | Capitalization | 12.5B |
---|---|---|---|---|---|
Net income 2024 * | 1.05B | Net income 2025 * | 1.2B | EV / Sales 2024 * | 6.86 x |
Net Debt 2024 * | 5.75B | Net Debt 2025 * | 5.93B | EV / Sales 2025 * | 6.25 x |
P/E ratio 2024 * |
11.9
x | P/E ratio 2025 * |
10.3
x | Employees | - |
Yield 2024 * |
3.14% | Yield 2025 * |
3.42% | Free-Float | 95.08% |
Latest transcript on Royalty Pharma plc
1 day | +0.59% | ||
1 week | +1.34% | ||
Current month | -7.87% | ||
1 month | -7.57% | ||
3 months | -3.78% | ||
6 months | +1.23% | ||
Current year | -0.39% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 215 M€ | +11.68% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 27.98 | +0.58% | 2,578,317 |
24-04-23 | 27.82 | 0.00% | 4,682,024 |
24-04-22 | 27.82 | -1.21% | 2,720,444 |
24-04-19 | 28.16 | +0.97% | 1,775,773 |
24-04-18 | 27.89 | +1.01% | 2,091,901 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.39% | 12.5B | |
+25.61% | 660B | |
+22.52% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+13.13% | 219B | |
-9.65% | 196B | |
+6.35% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- RPRX Stock